Clinical Trial

Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Trial Details
NCT Number NCT07411729
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: NG Biotech, Commissariat A L'energie Atomique
Conditions Emerging Infectious Diseases, Communicable Diseases, Biological Warfare Agents, Zoonoses, Disease Outbreaks
Enrollment 800 participants
Start Date 2024-06-03
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17